High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

Daniel J. McGrail; P.G. Pilié; N.U. Rashid; Leonie Voorwerk; Maarten Slagter; Marleen Kok; Eric Jonasch; Mustafa Khasraw; A Heimberger; Bora Lim; Naoto T. Ueno; JK Litton; Renata Ferrarotto; JT Chang; SL Moulder; S.-Y. Lin

doi:10.1016/j.annonc.2021.02.006

Keywords

MedicineBlockadeImmune checkpointCancerMutationImmune systemOncologyInternal medicineImmunologyGeneticsGeneReceptor

Affiliated Institutions

Related Publications

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Matthew D. Hellmann , Tavi Nathanson , Hira Rizvi +29 more

Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequen...

2018 Cancer Cell 1147 citations

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi , Matthew D. Hellmann , Alexandra Snyder +21 more

Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this...

2015 Science 7740 citations

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Timothy A. Chan , Mark Yarchoan , Elizabeth M. Jaffee +4 more

Abstract Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/...

2018 Annals of Oncology 2769 citations

Immune checkpoint signaling and cancer immunotherapy

Xing He , Chenqi Xu

Abstract Immune checkpoint blockade therapy has become a major weapon in fighting cancer. Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such a...

2020 Cell Research 1257 citations

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

Valsamo Anagnostou , Kellie N. Smith , Patrick M. Forde +26 more

Abstract Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the ...

2016 Cancer Discovery 853 citations

Publication Info

Year: 2021
Type: article
Volume: 32
Issue: 5
Pages: 661-672
Citations: 987
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

987

OpenAlex

Cite This

APA Style

                            
                                
                                    Daniel J. McGrail, 
                                
                                    P.G. Pilié, 
                                
                                    N.U. Rashid
                                
                                et al.
                            
                            (2021). 
                            High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. 
                            Annals of Oncology
                            , 32
                            (5)
                            , 661-672.
                            https://doi.org/10.1016/j.annonc.2021.02.006
                        

Identifiers

DOI: 10.1016/j.annonc.2021.02.006